{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:50:54Z","timestamp":1790841054580,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA214043"],"award-info":[{"award-number":["R01 CA214043"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["1018894"],"award-info":[{"award-number":["1018894"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anglo-American Charity Ltd. and Mr. Chris Hill"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>New treatment options for ovarian cancer are urgently required. Tumor-associated macrophages (TAMs) are an attractive target for therapy; repolarizing TAMs from M2 (pro-tumor) to M1 (anti-tumor) phenotypes represents an important therapeutic goal. We have previously shown that upregulated NF-kappaB (NF-\u03baB) signaling in macrophages promotes M1 polarization, but effects in the context of ovarian cancer are unknown. Therefore, we aimed to investigate the therapeutic potential of increasing macrophage NF-\u03baB activity in immunocompetent mouse models of ovarian cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We have generated a transgenic mouse model, termed IKFM, which allows doxycycline-inducible overexpression of a constitutively active form of IKK2 (cIKK2) specifically within macrophages. The IKFM model was used to evaluate effects of increasing macrophage NF-\u03baB activity in syngeneic murine TBR5 and ID8-Luc models of ovarian cancer in two temporal windows: 1) in established tumors, and 2) during tumor implantation and early tumor growth. Tumor weight, ascites volume, ascites supernatant and cells, and solid tumor were collected at sacrifice. Populations of macrophages and T cells within solid tumor and\/or ascites were analyzed by immunofluorescent staining and qPCR, and soluble factors in ascitic fluid were analyzed by ELISA. Comparisons of control versus IKFM groups were performed by 2-tailed Mann-Whitney test, and a <jats:italic>P<\/jats:italic>-value &lt;\u20090.05 was considered statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Increased expression of the cIKK2 transgene in TAMs from IKFM mice was confirmed at the mRNA and protein levels. Tumors from IKFM mice, regardless of the timing of doxycycline (dox) administration, demonstrated greater necrosis and immune infiltration than control tumors. Analysis of IKFM ascites and tumors showed sustained shifts in macrophage populations away from the M2 and towards the anti-tumor M1 phenotype. There were also increased tumor-infiltrating CD3<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup> T cells in IKFM mice, accompanied by higher levels of CXCL9, a T cell activating factor secreted by macrophages, in IKFM ascitic fluid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In syngeneic ovarian cancer models, increased canonical NF-\u03baB signaling in macrophages promoted anti-tumor TAM phenotypes and increased cytotoxic T cell infiltration, which was sufficient to limit tumor progression. This may present a novel translational approach for ovarian cancer treatment, with the potential to increase responses to T cell-directed therapy in future studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07450-8","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T09:05:57Z","timestamp":1602061557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Alyssa A.","family":"Hoover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetra H.","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennady","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan B.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Barham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1636-7942","authenticated-orcid":false,"given":"Fiona E.","family":"Yull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"issue":"4","key":"7450_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7450_CR2","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2(1):16061.","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"7450_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/diagnostics10030146","volume":"10","author":"F Borella","year":"2020","unstructured":"Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G, et al. Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives. Diagnostics. 2020;10(3):146.","journal-title":"Diagnostics"},{"issue":"10","key":"7450_CR4","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/j.1349-7006.2010.01652.x","volume":"101","author":"K Takaishi","year":"2010","unstructured":"Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010;101(10):2128\u201336.","journal-title":"Cancer Sci"},{"key":"7450_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137.","journal-title":"Front Oncol"},{"key":"7450_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","volume":"66","author":"P Allavena","year":"2008","unstructured":"Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hemat. 2008;66:1\u20139.","journal-title":"Crit Rev Oncol Hemat"},{"key":"7450_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549\u201355.","journal-title":"Trends Immunol"},{"key":"7450_CR8","doi-asserted-by":"crossref","unstructured":"Gupta V, Yull F, Khabele D. Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers (Basel). 2018;10(10):366.","DOI":"10.3390\/cancers10100366"},{"issue":"3","key":"7450_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"7450_CR10","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1158\/0008-5472.CAN-04-4262","volume":"65","author":"C Guiducci","year":"2005","unstructured":"Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437\u201346.","journal-title":"Cancer Res"},{"issue":"2","key":"7450_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4049\/jimmunol.174.2.636","volume":"174","author":"P Sinha","year":"2005","unstructured":"Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174(2):636\u201345.","journal-title":"J Immunol"},{"issue":"1","key":"7450_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12307-015-0174-x","volume":"9","author":"SA Almatroodi","year":"2016","unstructured":"Almatroodi SA, McDonald CF, Darby IA, Pouniotis DS. Characterization of M1\/M2 tumour-associated macrophages (TAMs) and Th1\/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron. 2016;9(1):1\u201311.","journal-title":"Cancer Microenviron"},{"issue":"5","key":"7450_CR13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1182\/blood-2005-01-0428","volume":"107","author":"SK Biswas","year":"2006","unstructured":"Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-\u03baB and enhanced IRF-3\/STAT1 activation). Blood. 2006;107(5):2112\u201322.","journal-title":"Blood"},{"issue":"1","key":"7450_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.","journal-title":"J Hematol Oncol"},{"key":"7450_CR15","first-page":"614","volume":"5","author":"N Wang","year":"2014","unstructured":"Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front Immunol. 2014;5:614.","journal-title":"Front Immunol"},{"key":"7450_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2015.12.016","volume":"56","author":"JM Hansen","year":"2016","unstructured":"Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016;56:131\u201343.","journal-title":"Eur J Cancer"},{"key":"7450_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2368249","volume":"2019","author":"MAF Yahaya","year":"2019","unstructured":"Yahaya MAF, Lila MAM, Ismail S, Zainol M, Afizan NARNM. Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. J Immunol Res. 2019;2019:1\u20139.","journal-title":"J Immunol Res"},{"issue":"5","key":"7450_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1189\/jlb.0310153","volume":"88","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Lewis CE. NF-\u03baB as a central regulator of macrophage function in tumors. J Leukoc Biol. 2010;88(5):877\u201384.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"7450_CR19","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/bcr2935","volume":"13","author":"L Connelly","year":"2011","unstructured":"Connelly L, Barham W, Onishko HM, Chen L, Sherrill TP, Zabuawala T, et al. NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model. Breast Cancer Res. 2011;13(4):R83.","journal-title":"Breast Cancer Res"},{"issue":"23","key":"7450_CR20","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1158\/0008-5472.CAN-06-1867","volume":"66","author":"A Saccani","year":"2006","unstructured":"Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66(23):11432\u201340.","journal-title":"Cancer Res"},{"issue":"24","key":"7450_CR21","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1158\/0008-5472.CAN-14-1091","volume":"74","author":"J Yang","year":"2014","unstructured":"Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, et al. Myeloid IKK promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res. 2014;74(24):7274\u201384.","journal-title":"Cancer Res"},{"issue":"6","key":"7450_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. \u201cRe-educating\u201d tumor-associated macrophages by targeting NF-\u03baB. J Exp Med. 2008;205(6):1261\u20138.","journal-title":"J Exp Med"},{"key":"7450_CR23","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2147\/IJN.S93483","volume":"11","author":"RA Ortega","year":"2016","unstructured":"Ortega RA, Barham W, Sharman K, Tikhomirov O, Giorgio TD, Yull FE. Manipulating the NF-kappaB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions. Int J Nanomedicine. 2016;11:2163\u201377.","journal-title":"Int J Nanomedicine"},{"issue":"16","key":"7450_CR24","doi-asserted-by":"publisher","first-page":"16756","DOI":"10.1021\/acsomega.9b01465","volume":"4","author":"EB Glass","year":"2019","unstructured":"Glass EB, Masjedi S, Dudzinski SO, Wilson AJ, Duvall CL, Yull FE, et al. Optimizing mannose \u201cclick\u201d conjugation to polymeric nanoparticles for targeted siRNA delivery to human and murine macrophages. ACS Omega. 2019;4(16):16756\u201367.","journal-title":"ACS Omega"},{"issue":"4","key":"7450_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585\u201391.","journal-title":"Carcinogenesis"},{"issue":"18","key":"7450_CR26","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1158\/0008-5472.CAN-06-1495","volume":"66","author":"D Xing","year":"2006","unstructured":"Xing D, Orsulic S. A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma. Cancer Res. 2006;66(18):8949\u201353.","journal-title":"Cancer Res"},{"issue":"19","key":"7450_CR27","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1073\/pnas.0502256102","volume":"102","author":"D Xing","year":"2005","unstructured":"Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A. 2005;102(19):6936\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"7450_CR28","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.18632\/oncotarget.3860","volume":"6","author":"AJ Wilson","year":"2015","unstructured":"Wilson AJ, Fadare O, Beeghly-Fadiel A, Son D-S, Liu Q, Zhao S, et al. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015;6(25):21353\u201368.","journal-title":"Oncotarget"},{"issue":"1","key":"7450_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-015-0060-6","volume":"3","author":"JB Liao","year":"2015","unstructured":"Liao JB, Ovenell KJ, Curtis EEM, Cecil DL, Koehnlein MR, Rastetter LR, et al. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. J Immunother Cancer. 2015;3(1):16.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"7450_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","volume":"11","author":"WD Dupont","year":"1990","unstructured":"Dupont WD, Plummer WD. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2):116\u201328.","journal-title":"Control Clin Trials"},{"issue":"4","key":"7450_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"3","key":"7450_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ygyno.2018.03.049","volume":"149","author":"AJ Wilson","year":"2018","unstructured":"Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol. 2018;149(3):575\u201384.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"7450_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1757-2215-6-63","volume":"6","author":"AJ Wilson","year":"2013","unstructured":"Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee H-J, et al. Tracking NF-\u03baB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013;6(1):63.","journal-title":"J Ovarian Res"},{"issue":"10","key":"7450_CR34","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1091\/mbc.e08-02-0139","volume":"19","author":"AJ Wilson","year":"2008","unstructured":"Wilson AJ, Byun D-S, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008;19(10):4062\u201375.","journal-title":"Mol Biol Cell"},{"key":"7450_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s12885-015-1652-8","volume":"15","author":"W Barham","year":"2015","unstructured":"Barham W, Chen L, Tikhomirov O, Onishko H, Gleaves L, Stricker TP, et al. Aberrant activation of NF-\u03baB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer. 2015;15:647.","journal-title":"BMC Cancer"},{"issue":"12","key":"7450_CR36","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/onc.2010.521","volume":"30","author":"L Connelly","year":"2010","unstructured":"Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, et al. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene. 2010;30(12):1402\u201312.","journal-title":"Oncogene"},{"key":"7450_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-015-0463-5","volume":"14","author":"AJ Wilson","year":"2015","unstructured":"Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Mol Cancer. 2015;14:192.","journal-title":"Mol Cancer"},{"issue":"9","key":"7450_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/pin.12440","volume":"66","author":"M Takeya","year":"2016","unstructured":"Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int. 2016;66(9):491\u2013505.","journal-title":"Pathol Int"},{"issue":"6","key":"7450_CR39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885\u2013900.e10.","journal-title":"Cancer Cell"},{"issue":"5","key":"7450_CR40","doi-asserted-by":"publisher","first-page":"e1424672","DOI":"10.1080\/2162402X.2018.1424672","volume":"7","author":"S Lieber","year":"2018","unstructured":"Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Bronger H, et al. Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology. 2018;7(5):e1424672.","journal-title":"Oncoimmunology."},{"issue":"31","key":"7450_CR41","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541\u20133.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7450_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2018.09.005","volume":"151","author":"W Wang","year":"2018","unstructured":"Wang W, Zou W, Liu JR. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecol Oncol. 2018;151(1):1\u20133.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"7450_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29(1):235\u201371.","journal-title":"Annu Rev Immunol"},{"issue":"3\u20134","key":"7450_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","volume":"130","author":"C Thallinger","year":"2018","unstructured":"Thallinger C, F\u00fcreder T, Preusser M, Heller G, M\u00fcllauer L, H\u00f6ller C, et al. Review of cancer treatment with immune checkpoint inhibitors. Wien Klin Wochenschr. 2018;130(3\u20134):85\u201391.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"7450_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"P Savas","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7450_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471\u201394.","journal-title":"Angiogenesis"},{"issue":"5","key":"7450_CR47","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286\u2013301.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"7450_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger H, Singer J, Windm\u00fcller C, Reuning U, Zech D, Delbridge C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 2016;115(5):553\u201363.","journal-title":"Br J Cancer"},{"issue":"2","key":"7450_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/bj20030842","volume":"376","author":"M Hiroi","year":"2003","unstructured":"Hiroi M, Ohmori Y. Constitutive nuclear factor \u03baB activity is required to elicit interferon-\u03b3-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem J. 2003;376(2):393\u2013402.","journal-title":"Biochem J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07450-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T02:10:00Z","timestamp":1633572600000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7450"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07450-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Vanderbilt University Institutional Animal Care and Use Committee and were conducted in accordance with American Association for Laboratory Animal Science (AALAS) and ARRIVE guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"970"}}